FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

AJANTPHARM

2,315.45
-79.25 (-3.31%)
Updated 01:45 30/07 IST

AJANTPHARM Buy or Sell - FrontPage Forums

2 Users have submitted 2 trade ideas of Rs. 45,814 for AJANTPHARM
Disclaimer
100% Bullish
0% Bearish

AJANTPHARM Buy or Sell - Brokerage Reports

No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
2030
Consensus Potential
-17.97%
See AJANTPHARM Share Price Targets >>

AJANTPHARM Ratings

Long term AJANTPHARM rating by FrontPage users
3/5 (1 Ratings)
Find answers to all your questions on live AJANTPHARM message board: Is AJANTPHARM buy or sell? Should I buy AJANTPHARM shares? Why are AJANTPHARM shares falling? Should I invest in AJANTPHARM stock?

  1. Home
  2. AJANTPHARM Forum

AJANTPHARM Share Price Discussion

N
Reputation: 15,707 • Just now
Buy Ajanta Pharma, target price Rs 2780: Motilal Oswal
Ajanta Pharma Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 20260.98 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Reply

✍️ Stocks in News 📰🗞️
📌 Tech Mahindra: The company reported a sharp increase in profit at Rs 1,353.2 crore in Q1FY22 against Rs 1,081.4 crore in Q4FY21, revenue rose to Rs 10,197.6 crore from Rs 9,729.9 crore QoQ.
📌 Container Corporation of India: The company reported pro...
Read more...
Like
Reply
1
Reply

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹2,350
Price@Trade
₹2,350.45
Target Price
₹3,000
Stop Price
₹2,200
Valid Till
Jul 29, 2022 3:20 AM
Margin
₹23,500 approx for 10 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 7:56 AM

Update
Trade Entered
Entry Price
₹2,350
S
Reputation: 3,504 • Jul 28 5:22 AM
Shivansh in AJANTPHARM
#AJANTPHARM 818 High
2
Reply
S
Reputation: 3,504 • Jul 28 1:27 AM
Shivansh in AJANTPHARM
Watchlist or BO Stocks #AJANTPHARM Earlier too...
1
Reply
Like
Reply
P
Reputation: 0 • Jul 28 3:50 AM

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹2,325
Price@Trade
₹2,311.05
Target Price
₹2,355
Stop Price
₹2,295
Valid Till
Jul 28, 2021 3:20 AM
Margin
₹232,500 approx for 100 Qty
Status
Exited
Exit Price
₹2,332.05
Net P&L
+₹705 (+0.3%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 28 8:16 AM

Update
Trade Entered
Entry Price
₹2,325
Paddu @paddu
Jul 28 8:17 AM

Update
Exited
Exit Price
₹2,332.05
Net P&L
+₹705 (+0.3%)
O
Reputation: 0 • Jul 28 3:36 AM

Type
Sell
Instrument
AJANTPHARM
Entry Price
₹2,305
Price@Trade
₹2,302.65
Target Price
₹2,270
Stop Price
₹2,325
Valid Till
Jul 28, 2021 3:20 AM
Margin
₹23,050 approx for 10 Qty
Status
Stoploss Hit
Exit Price
₹2,325
Net P&L
-₹200 (-0.87%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 28 3:38 AM

Update
Trade Entered
Entry Price
₹2,305
TrackerBot @trackerbot
Jul 28 8:16 AM

Update
Stoploss Hit
Exit Price
₹2,325
V
Reputation: 0 • Jul 27 7:14 AM

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹2,243.9
Price@Trade
₹2,243.9
Target Price
₹3,000
Stop Price
₹2,000
Valid Till
Aug 27, 2021 3:20 AM
Margin
₹112,195 approx for 50 Qty
Status
Exited
Exit Price
₹2,245
Net P&L
+₹55 (+0.05%)
Like
Reply (1)
swap_vert
Trade
See all replies
Viccy @viccy
Jul 27 8:06 AM

Update
Exited
Exit Price
₹2,245
Net P&L
+₹55 (+0.05%)
S
Reputation: 3,504 • Jul 27 5:43 AM
2
Reply (1)
See all replies

Only 2 likes , You people can't appreciate other, Earlier you all did Same
Like
Reply

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹2,234
Price@Trade
₹2,227.3
Target Price
₹2,450
Stop Price
₹2,120
Valid Till
Aug 26, 2021 3:20 AM
Margin
₹670,200 approx for 300 Qty
Status
Exited
Exit Price
₹2,298.95
Net P&L
+₹19,485 (+2.91%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 26 7:35 AM

Update
Trade Entered
Entry Price
₹2,234

Update
Exited
Exit Price
₹2,298.95
Net P&L
+₹19,485 (+2.91%)

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹2,231.4
Price@Trade
₹2,231.4
Target Price
₹2,500
Stop Price
₹2,000
Valid Till
Jul 26, 2022 3:20 AM
Margin
₹22,314 approx for 10 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹2,141.2
Price@Trade
₹2,141.2
Target Price
₹2,150
Stop Price
₹34
Valid Till
Jul 20, 2022 3:20 AM
Margin
₹8,564.8 approx for 4 Qty
Status
Target Achieved
Exit Price
₹2,150
Net P&L
+₹35.2 (+0.41%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 20 8:26 AM

Update
Target Achieved
Exit Price
₹2,150
K
Reputation: 0 • Jul 5 2:55 AM

Type
Sell
Instrument
AJANTPHARM
Entry Price
₹2,150  ₹2,148.9
Price@Trade
₹2,148.4
Target Price
₹2,100
Stop Price
₹2,165
Valid Till
Jul 5, 2021 3:20 AM
Margin
₹2,148.9 approx for 1 Qty
Status
Exited
Exit Price
₹2,142.55
Net P&L
+₹6.35 (+0.3%)

Like
Reply (3)
swap_vert
Trade
See all replies
KGF @sangamkumar
Jul 5 2:56 AM

Update
Entry Price Modified
Price @ Update
₹2,148.9
Original Entry Price
₹2,150
New Entry Price
₹2,148.9
TrackerBot @trackerbot
Jul 5 2:56 AM

Update
Trade Entered
Entry Price
₹2,148.9
KGF @sangamkumar
Jul 5 5:04 AM

Update
Exited
Exit Price
₹2,142.55
Net P&L
+₹6.35 (+0.3%)

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹2,102
Price@Trade
₹2,102
Target Price
₹2,200
Stop Price
₹2,080
Valid Till
Jul 2, 2021 3:20 AM
Margin
₹735,700 approx for 350 Qty
Status
Exited
Exit Price
₹2,088.75
Net P&L
-₹4,637.5 (-0.63%)
Like
Reply (1)
swap_vert
Trade
See all replies

Update
Exited
Exit Price
₹2,088.75
Net P&L
-₹4,637.5 (-0.63%)

Type
Sell
Instrument
AJANTPHARM
Entry Price
₹2,078
Price@Trade
₹2,078
Target Price
₹2,000
Stop Price
₹2,100
Valid Till
Jul 2, 2021 3:20 AM
Margin
₹831,200 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹2,100
Net P&L
-₹8,800 (-1.06%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 1 8:55 AM

Update
Stoploss Hit
Exit Price
₹2,100

Type
Sell
Instrument
AJANTPHARM
Entry Price
₹2,094.7
Price@Trade
₹2,094.7
Target Price
₹2,050
Stop Price
₹2,110
Valid Till
Jul 2, 2021 3:20 AM
Margin
₹837,880 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹2,110
Net P&L
-₹6,120 (-0.73%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 1 8:44 AM

Update
Stoploss Hit
Exit Price
₹2,110

Type
Sell
Instrument
AJANTPHARM
Entry Price
₹2,098.9
Price@Trade
₹2,098.9
Target Price
₹2,070
Stop Price
₹2,110
Valid Till
Jul 1, 2021 3:20 AM
Margin
₹104,945 approx for 50 Qty
Status
Stoploss Hit
Exit Price
₹2,110
Net P&L
-₹555 (-0.53%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 1 6:11 AM

Update
Stoploss Hit
Exit Price
₹2,110
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • AJANTPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization9,036.61
    Enterprise Value9,000.74
    Price to Earnings29.08
    Price to Book Value4.22
    Return on Capital Employed0.29
    Return on Equity0.22
    Face Value2
    Dividend YieldNA
  • AJANTPHARM - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    2-Feb-21Motilal OswalBuy2,030
    27-Feb-20Motilal OswalBuy1,655
    6-Feb-20Motilal OswalBuy1,435
    1-Aug-19ICICIdirect.comHold1,010
    2-Feb-19Reliance SecuritiesBuy1,225
    AJANTPHARM Brokerage Price Target
  • AJANTPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 292331.9243523122394.7
    Jul 28226323652218.552331.9
    Jul 27224222622215.852248.7
    Jul 262166.32242.952147.652216.55
    Jul 232129.452179.952117.052166.3
  • AJANTPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹2,179.59
    30 Day Moving Average₹2,118.6
    50 Day Moving Average₹2,052.71
    100 Day Moving Average₹1,937.33
    200 Day Moving Average₹1,800.94
  • AJANTPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,830.451,822.710
    Operating Profit546.81636.01-0.14
    Profit Before Tax562.44640.65-0.12
    Net Income427.52499.81-0.14
  • AJANTPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,1431,931.50.11
    Total Liabilities379381.35-0.01
    Total Assets2,5222,312.850.09
  • AJANTPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity219.16529.06-0.59
    Cash from Investing Activity-201.12-349.66-0.42
    Cash from Financing Activity-0.54-194.08-1
    Net Cash Flow17.5-14.68-2.19
  • AJANTPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.180.29
    Return on Equity0.220.33
    Return on Capital Employed0.290.43
  • AJANTPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.35
    3 Year CAGR Growth in Operating Profit0.17
    3 Year CAGR Growth in EBIDTA0.24
    3 Year CAGR Growth in Net Income0.4
    3 Yr CAGR Growth - Diluted EPS0.39
  • AJANTPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.18
    5 Year CAGR Growth in Operating Profit1.64
    5 Year CAGR Growth in EBIDTA1.89
    5 Year CAGR Growth in Net Income3.23
    3 Yr CAGR Growth - Diluted EPS0.12
  • AJANTPHARM - Recent News

    keyboard_arrow_down
    NewsBot
    Just now
    Buy Ajanta Pharma, target price Rs 2780: Motilal Oswal
    The Economic Times
    NewsBot
    Jun 2 12:16 PM
    Confused about which stocks to buy? Raamdeo Agrawal offers a few tips
    The Economic Times
    NewsBot
    May 9 9:06 AM
    Ajanta Pharma earmarks Rs 250 crore capex for current fiscal
    The Economic Times
    NewsBot
    May 6 3:46 AM
    Stock market update: 90 stocks hit 52-week highs on NSE
    The Economic Times
    NewsBot
    Apr 30 11:46 AM
    Ajanta Pharma Q4 results: Net profit rises 23% to Rs 159 cr
    The Economic Times
    NewsBot
    Mar 9 5:11 AM
    Buy Ajanta Pharma, target price Rs 2030: Motilal Oswal
    The Economic Times
    NewsBot
    Feb 14 5:38 AM
    Buy Ajanta Pharma; Target Of Rs 2030: Motilal Oswal
    Moneycontrol
    NewsBot
    Feb 4 10:53 AM
    Ajanta Pharma Share Price Jumps 7%, Hits 52-week High As Q3 PAT Zooms 64%
    Moneycontrol
    NewsBot
    Feb 4 10:53 AM
    NewsBot
    Feb 4 10:53 AM
    Ajanta Pharma Q3 Net Profit Up 64% To Rs 177 Crore
    Moneycontrol
  • AJANTPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • AJANTPHARM - More Information

    keyboard_arrow_down

    Ajanta Pharma Limited:
    Ajanta Pharma Limited is among the nation’s most prestigious pharmaceutical company, announcing their mission to serve the global healthcare with empathy, innovation and technology. The firm was established in the year of 1973 with headquarter at Mumbai. The company is announcing to ‘Serve Healthcare Needs Worldwide’. The company is aiming to use cutting edge technology to bring innovations.
    The company is developing its business internationally to achieve their aim. The company is currently pursuing its business in India, USA and around thirty other countries in Asia, Africa, CIS and the Middle East. With a Research and Development team enriched with more than 750 scientists, Ajanta Pharma is possessing a workforce of more than 7,500 employees all over the world. The company has currently 1,400 products in different countries around the globe with a deep focus on the market of USA, expecting a good outcome. Ajanta Pharma has been manufacturing anti-malarial products for the health programmes in Africa approved by WHO.
    Company Information:
    Soon after its inception in 1973, Ajanta Pharma Limited has been pursuing tremendous achievements in its journey towards the golden jubilee. In 1979, the company produced branded ‘Over The Counter’ products along with developing its first manufacturing facility set-up at Chikalthana, India. By seven years the firm set up its second manufacturing facility at Paithan, India. By 1989, Ajanta Pharma reached a milestone of manufacturing more than 30 ‘Over The Counter’ products. The company intervened the international market for the first time in 1992. In 1995 the company developed its subsidiary at Mauritius with a manufacturing facility set-up. Millennium brought a credible achievement for the company while Ajanta Pharma had been enlisted in National Stock Exchange and Bombay Stock Exchange. The company intervened the domestic prescription market in 2002, introducing speciality segment force.
    As the company has been in the process of in traducing innovations, it developed its R&D facility at Kandivli. Establishing an Active Pharmaceutical Ingredient (API) Plant at Waluj in Aurangabad, the company got the approval of USFDA in 2007. In the same year, Ajanta Pharma developed a manufacturing facility in Aurangabad for rapid growth. The company received its international recognition in the same year by becoming the world’s first generic company to achieve WHO Geneva Pre-qualification for Anti-Malarial Drug. In 2010, Ajanta Pharma intervened the market of the Philippines through Ajanta Philippines Inc. Ophthalmology, Dermatology, Cardiology— these are the three segments where the company created its reign and emerged in the leading position in 2011.
    In the next year, the company achieved its place among the top ten pharmaceutical companies in Franco Africa. The company started its journey to explore the USA market in the year 2013. Ajanta Pharma inaugurated its Research & Development centre at Kandivli, Mumbai to expand its innovations and after that the business in a larger periphery. Inauguration of a new facility was done in Dahej, 2015 to fulfil the requirements of the USA market and WHO. Montelukas Sodium Oral Granules were announced to launch by Ajanta in 2015 along with the announcement of the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in the US market. In the year 2017, the company developed its new facility in Guwahati. In the same year, USFDA has approved Ajanta Pharma’s Dahej facility.
    The company is currently spending 9% of its revenue in Research & Development in the financial year of 2019-20. From 28 different nationalities, the company has appointed more than 7500 people as its permanent staff. The total income in the fiscal year of 2019-20 is 2076 crore INR; the company has been enjoying a net profit of 387 crore INR in the same financial year. The current EBITDA margin of the company in the current fiscal year of 2019-20 is 28%.
    The company is announcing its philosophy as first to create opportunities and then optimize them on fullest.
    How Ajanta Pharma Ltd, is categorised as Pharmaceuticals and Health Care Sector, and Pharmaceuticals Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Ajanta Pharma Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Ajanta Pharma Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020